glipizide has been researched along with Hyperglycemia, Postprandial in 23 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
Hyperglycemia, Postprandial: Abnormally high BLOOD GLUCOSE level after a meal.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the effects of sulfonylureas administered supraspinally on kainic acid (KA)-induced hippocampal neuronal cell death and hyperglycemia were studied in ICR mice." | 7.80 | Effect of tolbutamide, glyburide and glipizide administered supraspinally on CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice. ( Jung, JS; Kim, CH; Kim, SJ; Kim, SS; Lim, SM; Park, SH; Sim, YB; Suh, HW, 2014) |
| "Control of glycemia was classified and monitored and serum fructosamine and blood GHb concentrations were measured for 12 poorly controlled diabetic cats before and after improving glycemic control, 8 well-controlled treated diabetic cats before and after glycemic control deteriorated, and 5 cats with diabetes mellitus before and after onset of stress-induced hyperglycemia." | 7.70 | Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. ( Elliott, DA; Feldman, EC; Neal, LA; Nelson, RW; Reusch, CE, 1999) |
| "Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain." | 5.17 | Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. ( Fleck, P; Rosenstock, J; Wilson, C, 2013) |
| "This study was designed to compare the efficacy of acute premeal administration of glipizide versus nateglinide in controlling postprandial hyperglycemia in subjects with non-insulin-requiring type 2 diabetes." | 5.10 | Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. ( Burge, MR; Carroll, MF; Izard, A; Riboni, K; Schade, DS, 2002) |
| " In the present study, the effects of sulfonylureas administered supraspinally on kainic acid (KA)-induced hippocampal neuronal cell death and hyperglycemia were studied in ICR mice." | 3.80 | Effect of tolbutamide, glyburide and glipizide administered supraspinally on CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice. ( Jung, JS; Kim, CH; Kim, SJ; Kim, SS; Lim, SM; Park, SH; Sim, YB; Suh, HW, 2014) |
| "Control of glycemia was classified and monitored and serum fructosamine and blood GHb concentrations were measured for 12 poorly controlled diabetic cats before and after improving glycemic control, 8 well-controlled treated diabetic cats before and after glycemic control deteriorated, and 5 cats with diabetes mellitus before and after onset of stress-induced hyperglycemia." | 3.70 | Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. ( Elliott, DA; Feldman, EC; Neal, LA; Nelson, RW; Reusch, CE, 1999) |
| " Rats were given a subcutaneous injection of 1 g/kg glucosamine: this dose caused marked hyperglycemia and a decrease in hepatic glycogen, but does not alter blood insulin levels." | 3.66 | Glipizide and hepatic glycogenolysis. ( Bloch, K; Daturi, S; Tommasini, R, 1980) |
| "In this study, 148 patients with type 2 diabetes mellitus (T2DM) were assigned randomly to receive either glipizide alone or glipizide plus Aralia root bark extract (ARBE) for 8 weeks to test the effects of ARBE plus glipizide therapy on glycemic control and lipid profiles in these patients." | 2.80 | Effects of combined therapy with glipizide and Aralia root bark extract on glycemic control and lipid profiles in patients with type 2 diabetes mellitus. ( Fang, XF; Han, CC; Li, XM; Liu, XH; Ma, L, 2015) |
| " The decision to prescribe one of these three insulinotropic agents should be based on factors such as the patient's ability to comply with complex dosing regimens, the need to control fasting hyperglycemia, the risk of interprandial hypoglycemia, and pharmacoeconomic considerations, rather than postprandial glucose-lowering efficacy." | 2.71 | Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. ( Carroll, MF; Castro, M; Gutierrez, A; Schade, DS; Tsewang, D, 2003) |
| " This delay of absorption may be clinically relevant, since the efficacy of short-acting sulphonylureas is dependent upon the absorption rate of the drug." | 2.66 | Hyperglycaemia and absorption of sulphonylurea drugs. ( DeFronzo, RA; Groop, LC; Luzi, L; Melander, A, 1989) |
| "In patients with type 1 diabetes mellitus a quality of life decreases gradually with the duration of diabetes." | 2.41 | [The effect of improved glycemic control on quality of life in patients with type I and type II diabetes]. ( Grzeszczak, W, 2001) |
| "The quality of life of NIDDM patients can be improved by stricter glycaemic control, and thus can modify in the choice of therapeutic strategies and cost-benefit evaluation of intensive glycaemic control." | 2.40 | [Quality of life and non-insulin-dependent diabetes]. ( Tauber, JP, 1997) |
| " In this work, enhancement of the solubility and dissolution of the practically insoluble drug glipizide was achieved by formation of bionanocomposites (BNCs) using microwave-induced diffusion (MIND), which ultimately leads to bioavailability enhancement." | 1.39 | Microwave-generated bionanocomposites for solubility and dissolution enhancement of poorly water-soluble drug glipizide: in-vitro and in-vivo studies. ( Gattani, SG; Kushare, SS, 2013) |
| "During the hyperglycemic clamp in NIDDM subjects, the first-phase plasma insulin response was absent, and the second-phase insulin response was markedly impaired." | 1.27 | Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. ( DeFronzo, RA; Groop, L; Groop, PH; Luzi, L; Melander, A; Ratheiser, K; Simonson, DC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Schindler, MSZ | 1 |
| Calisto, JFF | 1 |
| Marins, K | 1 |
| Regginato, A | 1 |
| Mezzomo, H | 1 |
| Zanatta, AP | 1 |
| Radunz, AL | 1 |
| Mariot, MP | 1 |
| Dal Magro, J | 1 |
| Zanatta, L | 1 |
| Campbell, JM | 1 |
| Adanichkin, N | 1 |
| Kurmis, R | 1 |
| Munn, Z | 1 |
| Rosenstock, J | 1 |
| Wilson, C | 1 |
| Fleck, P | 1 |
| Kim, CH | 1 |
| Park, SH | 1 |
| Sim, YB | 1 |
| Kim, SS | 1 |
| Kim, SJ | 1 |
| Lim, SM | 1 |
| Jung, JS | 1 |
| Suh, HW | 1 |
| Liu, XH | 1 |
| Li, XM | 1 |
| Han, CC | 1 |
| Fang, XF | 1 |
| Ma, L | 1 |
| Kushare, SS | 1 |
| Gattani, SG | 1 |
| Carroll, MF | 2 |
| Izard, A | 1 |
| Riboni, K | 1 |
| Burge, MR | 1 |
| Schade, DS | 2 |
| Gutierrez, A | 1 |
| Castro, M | 1 |
| Tsewang, D | 1 |
| Vähätalo, M | 1 |
| Rönnemaa, T | 1 |
| Viikari, J | 1 |
| Kapoor, JR | 1 |
| Bloch, K | 1 |
| Daturi, S | 1 |
| Tommasini, R | 1 |
| Esmatjes, E | 1 |
| Vinuesa, P | 1 |
| Navarro, P | 1 |
| Rodriguez-Villar, C | 1 |
| Gomis, R | 1 |
| Vilardell, E | 1 |
| Schmitz, O | 1 |
| Lund, S | 1 |
| Bak, JF | 1 |
| Orskov, L | 1 |
| Andersen, PH | 1 |
| Møller, N | 1 |
| Rasmussen, O | 1 |
| Christiansen, JS | 1 |
| Pedersen, O | 1 |
| Jaber, LA | 1 |
| Lewis, NJ | 1 |
| Slaughter, RL | 1 |
| Neale, AV | 1 |
| Tauber, JP | 1 |
| Elliott, DA | 1 |
| Nelson, RW | 1 |
| Reusch, CE | 1 |
| Feldman, EC | 1 |
| Neal, LA | 1 |
| Martin, G | 1 |
| Rand, J | 1 |
| Grzeszczak, W | 1 |
| Pasmantier, R | 1 |
| Chaiken, RL | 1 |
| Hirsch, SR | 1 |
| Lebovitz, HE | 1 |
| Groop, LC | 1 |
| Luzi, L | 2 |
| DeFronzo, RA | 2 |
| Melander, A | 3 |
| Bitzén, PO | 1 |
| Scherstén, B | 1 |
| Wåhlin-Boll, E | 1 |
| Groop, L | 1 |
| Groop, PH | 1 |
| Ratheiser, K | 1 |
| Simonson, DC | 1 |
| Cederholm, J | 1 |
| Wibell, L | 1 |
4 reviews available for glipizide and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hypergl | 2018 |
[Quality of life and non-insulin-dependent diabetes].
Topics: Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; France; Glipizide; Humans; Hyperglycemia; | 1997 |
Current understanding of feline diabetes: part 2, treatment.
Topics: Animals; Blood Glucose; Body Weight; Cat Diseases; Cats; Diabetes Complications; Diabetes Mellitus; | 2000 |
[The effect of improved glycemic control on quality of life in patients with type I and type II diabetes].
Topics: Adaptation, Psychological; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glipizide; Humans; | 2001 |
8 trials available for glipizide and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2013 |
Effects of combined therapy with glipizide and Aralia root bark extract on glycemic control and lipid profiles in patients with type 2 diabetes mellitus.
Topics: Antioxidants; Aralia; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supplemen | 2015 |
Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glipizide; Huma | 2002 |
Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Delayed-Action Preparations | 2003 |
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice.
Topics: Administration, Oral; Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therap | 2007 |
The effect of stress on glycemic control in patients with type II diabetes during glyburide and glipizide therapy.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Femal | 1993 |
Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug The | 1990 |
Hyperglycaemia and absorption of sulphonylurea drugs.
Topics: Adult; Blood Glucose; Dose-Response Relationship, Drug; Drug Evaluation; Female; Gastric Emptying; G | 1989 |
11 other studies available for glipizide and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Characterization of the chemical profile and the effects of ethanolic extracts of Maytenus ilicifolia Mart. ex Reissek on glucose metabolism in normal hyperglycemic rats.
Topics: Alanine Transaminase; Animals; Blood Glucose; Disaccharides; Ethanol; Glipizide; Glucose; Glycogen; | 2021 |
Effect of tolbutamide, glyburide and glipizide administered supraspinally on CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
Topics: Animals; Blood Glucose; CA3 Region, Hippocampal; Cell Death; Glipizide; Glyburide; Hyperglycemia; Hy | 2014 |
Microwave-generated bionanocomposites for solubility and dissolution enhancement of poorly water-soluble drug glipizide: in-vitro and in-vivo studies.
Topics: Animals; Biological Availability; Chemistry, Pharmaceutical; Diffusion; Drug Delivery Systems; Drug | 2013 |
Postprandial hyperglycemia: are all sulfonylureas created equal?
Topics: Carbamates; Cyclohexanes; Glipizide; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Na | 2008 |
Glipizide and hepatic glycogenolysis.
Topics: Adrenalectomy; Animals; Blood Glucose; Dose-Response Relationship, Drug; Glipizide; Glucosamine; Hyp | 1980 |
The effect of hyperglycemia on glipizide absorption in NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glipizide; Glucose; Humans; Hyperglycemia; Hypogly | 1995 |
Effects of glipizide on glucose metabolism and muscle content of the insulin-regulatable glucose transporter (GLUT 4) and glycogen synthase activity during hyperglycaemia in type 2 diabetic patients.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glipizi | 1994 |
Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Cohort Studies; Diabetes Mellitus; Fructosamine; Glipizi | 1999 |
The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia.
Topics: Aged; Biological Availability; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glipizid | 1988 |
Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Gl | 1987 |
The impact of treatment on insulin release and relative peripheral resistance during the oral glucose tolerance test. A study of noninsulin-dependent diabetes mellitus and glucose intolerance.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Glip | 1986 |